PEPCK

PEPCK catalyzes the decarboxylation and phosphorylation of oxaloacetate (OAA) to form phosphoenolpyruvate (PEP), using GTP as the phosphate donor, releasing CO2 and GDP. This is the second step in gluconeogenesis, following pyruvate carboxylase's conversion of pyruvate to OAA in the mitochondria. Because OAA cannot cross the mitochondrial membrane directly, it is often converted to malate (via malate dehydrogenase) for transport to the cytosol, then reconverted to OAA before PEPCK acts—though the mitochondrial isoform can act directly on OAA within the mitochondria.

Regulation: PEPCK gene expression is transcriptionally regulated—induced by glucagon (via cAMP/PKA/CREB) and cortisol (via glucocorticoid response elements), and suppressed by insulin (via PI3K/Akt inhibiting FOXO1-mediated transcription). This makes PEPCK a major control point for hepatic glucose output during fasting states.

Clinical significance: PEPCK deficiency is a rare cause of hypoglycemia, lactic acidosis, hepatomegaly, and failure to thrive in infants, as gluconeogenesis is impaired. It shares clinical overlap with other gluconeogenic disorders like fructose-1,6-bisphosphatase deficiency and pyruvate carboxylase deficiency, causing fasting hypoglycemia with lactic acidosis (differentiating from glycogen storage diseases which may have different lactate patterns).

PEPCK is also a target of interest in diabetes research since its overexpression contributes to excessive hepatic glucose production in Type 2 diabetes, and its suppression is a goal of some antidiabetic therapies (e.g., metformin partially works by inhibiting mitochondrial glycerophosphate dehydrogenase, indirectly affecting gluconeogenic flux related to PEPCK-dependent pathways).

High-yield associations: Biotin is required for pyruvate carboxylase (upstream step), NOT for PEPCK. PEPCK requires GTP, not ATP, distinguishing it from other kinase reactions in glycolysis/gluconeogenesis.